Lowers IOP in open-angle glaucoma or ocular hypertension.
Adults and children 2 yr of age and older: Ophthalmic Instill 1 drop into affected eye(s) 3 times daily (approximately 8 h apart). If using other topical ophthalmic drugs, separate each medication by at least 5 min.
Reduces aqueous humor production and increases uveoscleral outflow.
Coadministration of MAOIs.
CV: Hypertension; palpitations.
CNS: Headache; fatigue; drowsiness; dizziness; depression; anxiety; syncope.
EENT: Dry mouth; ocular hyperemia, burning, and stinging; blurred vision; foreign body sensation; conjunctival follicles; ocular allergy; ocular pruritus; corneal staining and erosion; photophobia; eyelid erythema and edema; ocular aching and pain; ocular dryness; tearing; conjunctival edema; blepharitis; ocular irritation; conjunctival blanching; abnormal vision; lid crusting; conjunctival hemorrhage; abnormal taste; conjunctival discharge; nasal dryness.
GI: GI symptoms.
RESP: Upper respiratory tract symptoms.
OTHER: Asthenia; muscle pain.
Antihypertensives, beta blockers, cardiac glycosides
Brimonidine may reduce pulse and BP; use with caution.
CNS depressants (eg, alcohol, anesthetics, barbiturates, opiates, sedative)
Additive or potentiating CNS depressant effect.
Concurrent use contraindicated; discontinue MAOIs at least 14 days before initiating therapy.
May decrease the effect of brimonidine by altering the metabolism and uptake of circulating amines.
Alpha adrenergic agonist
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal